[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594165":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":40,"centralContacts":45,"locations":53,"responsibleParty":237,"collaborators":239,"id":242,"slug":243,"hasResults":244,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":244,"sex":250,"minAge":251,"maxAge":31,"enrollmentInfo":252,"targetDuration":31,"studyType":255,"phases":256,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":56,"whyStopped":31,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":275},{"fullName":5,"class":6},"Instituto de Investigación Biomédica de Salamanca","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Radiotherapy Arm (45 Gy BID)","ACTIVE_COMPARATOR","Patients in this group will receive concurrent chemoradiotherapy consisting of cisplatin and etoposide with standard-dose thoracic radiotherapy: 45 Gy administered in 30 fractions of 1.5 Gy twice daily (BID).",[13],"Radiation: Thoracic Radiotherapy 45 Gy BID",{"label":15,"type":16,"description":17,"interventionNames":18},"Escalated Dose Radiotherapy Arm (60 Gy BID)","EXPERIMENTAL","Patients in this group will receive the same chemotherapy as Arm 1, combined with an escalated thoracic radiotherapy dose: 60 Gy delivered in 40 fractions of 1.5 Gy twice daily (BID). Dose may be reduced to 54 Gy if organs at risk exceed tolerance.",[19],"Radiation: Thoracic Radiotherapy 60 Gy BID",{"label":21,"type":16,"description":22,"interventionNames":23},"Simultaneous Integrated Boost Radiotherapy Arm (45-54 Gy BID)","Patients in this group will receive the same chemotherapy as in other arms, with thoracic radiotherapy delivered as a simultaneous integrated boost (SIB): 45 Gy to the general target volume and 54 Gy to the high-risk clinical target volume (CTV) in 30 fractions BID.",[24],"Radiation: Thoracic Radiotherapy SIB 45-54 Gy BID",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"RADIATION","Thoracic Radiotherapy 45 Gy BID","45 Gy delivered in 30 fractions of 1.5 Gy twice daily over three weeks, with 95% of the planning target volume (PTV) receiving at least 95% of the prescribed dose.",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Thoracic Radiotherapy 60 Gy BID","60 Gy delivered in 40 fractions of 1.5 Gy BID. A minimum dose of 54 Gy will be accepted if organ-at-risk tolerance is exceeded.",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Thoracic Radiotherapy SIB 45-54 Gy BID","45 Gy in 30 fractions (1.5 Gy BID) to PTV and 54 Gy in 30 fractions (1.8 Gy BID) to high-risk CTV. Both delivered simultaneously using 3D conformal planning.",[21],[41],{"name":42,"affiliation":43,"role":44},"Iñigo San Miguel Arregui, MD PhD","Institute of Biomedical Research of Salamanca","PRINCIPAL_INVESTIGATOR",[46,50],{"name":42,"role":47,"phone":48,"phoneExt":31,"email":49},"CONTACT","+34 923291600","isanm@saludcastillayleon.es",{"name":51,"role":47,"phone":48,"phoneExt":31,"email":52},"Cristina Cigarral García, MD","ccigarral@usal.es",[54,86,100,113,126,139,152,162,175,188,201,214,224],{"facility":55,"status":56,"city":57,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Complejo Asistencial Universitario de Salamanca","RECRUITING","Salamanca","37007","Spain","ES",{"type":62,"coordinates":63},"Point",[64,65],-5.66388,40.96882,{"lat":65,"lon":64},[68,69,71,73,75,76,78,80,82,84],{"name":42,"role":47,"phone":48,"phoneExt":31,"email":49},{"name":51,"role":70,"phone":31,"phoneExt":31,"email":31},"SUB_INVESTIGATOR",{"name":72,"role":70,"phone":31,"phoneExt":31,"email":31},"Edel Del Barco Morillo, MD PhD",{"name":74,"role":70,"phone":31,"phoneExt":31,"email":31},"Lorena Bellido Hernández, MD PhD",{"name":42,"role":44,"phone":31,"phoneExt":31,"email":31},{"name":77,"role":70,"phone":31,"phoneExt":31,"email":31},"Juan Alejandro Cascón Hernández, MD",{"name":79,"role":70,"phone":31,"phoneExt":31,"email":31},"Irene Jiménez García, MD",{"name":81,"role":70,"phone":31,"phoneExt":31,"email":31},"Paloma Garcia-Talavera San Miguel, MD PhD",{"name":83,"role":70,"phone":31,"phoneExt":31,"email":31},"Marta Rodríguez González, MD PhD",{"name":85,"role":70,"phone":31,"phoneExt":31,"email":31},"Francisco Javier Martín Vallejo, PhD",{"facility":87,"status":88,"city":89,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Hospital Universitario de Torrecardenas","NOT_YET_RECRUITING","Almería",{"type":62,"coordinates":91},[92,93],-2.45974,36.83814,{"lat":93,"lon":92},[96],{"name":97,"role":47,"phone":98,"phoneExt":31,"email":99},"Manuel Luna, PhD","+34 950 016 000","luna.me92@gmail.com",{"facility":101,"status":88,"city":102,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Hospital Universitario de Cruces","Barakaldo",{"type":62,"coordinates":104},[105,106],-2.98813,43.29639,{"lat":106,"lon":105},[109],{"name":110,"role":47,"phone":111,"phoneExt":31,"email":112},"Jon Cacicedo, PhD","+34 946 00 60 00","jon.cacicedofernandezbobadilla@osakidetza.eus",{"facility":114,"status":88,"city":115,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Instituto Catalán de Oncología","Girona",{"type":62,"coordinates":117},[118,119],2.82493,41.98311,{"lat":119,"lon":118},[122],{"name":123,"role":47,"phone":124,"phoneExt":31,"email":125},"Ester Oliva, PhD","+34 972 22 51 58","eoliva@iconcologia.net",{"facility":127,"status":88,"city":128,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Hospital Dr. Negrin","Las Palmas de Gran Canaria",{"type":62,"coordinates":130},[131,132],-15.41573,28.10178,{"lat":132,"lon":131},[135],{"name":136,"role":47,"phone":137,"phoneExt":31,"email":138},"Marta Lloret, PhD","+34 928 45 00 00","mllosae@hotmail.com",{"facility":140,"status":88,"city":141,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Hospital Gregorio Marañon","Madrid",{"type":62,"coordinates":143},[144,145],-3.70256,40.4165,{"lat":145,"lon":144},[148],{"name":149,"role":47,"phone":150,"phoneExt":31,"email":151},"Marina Santos, PhD","+34 915 86 80 00","marinasantos15@hotmail.com",{"facility":153,"status":56,"city":141,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":154,"geoPoint":156,"contacts":157},"Hospital Ramon y Cajal",{"type":62,"coordinates":155},[144,145],{"lat":145,"lon":144},[158],{"name":159,"role":47,"phone":160,"phoneExt":31,"email":161},"Margarita Martín, PhD","+34 913 36 80 00","oncomarga@gmail.com",{"facility":163,"status":88,"city":164,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"Hospital Universitario Virgen de Arrixaca","Murcia",{"type":62,"coordinates":166},[167,168],-1.13004,37.98704,{"lat":168,"lon":167},[171],{"name":172,"role":47,"phone":173,"phoneExt":31,"email":174},"Francisco Javier López, PhD","+34 968 36 95 00","flopezsoler@hotmail.com",{"facility":176,"status":88,"city":177,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"Hospital Marques de Valdecilla","Santander",{"type":62,"coordinates":179},[180,181],-3.80493,43.46589,{"lat":181,"lon":180},[184],{"name":185,"role":47,"phone":186,"phoneExt":31,"email":187},"Ivan Díaz de Cerio, PhD","+34 942 20 25 20","ivancerio@hotmail.com",{"facility":189,"status":88,"city":190,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Complejo Hospitalario Universitario de Santiago","Santiago de Compostela",{"type":62,"coordinates":192},[193,194],-8.54569,42.88052,{"lat":194,"lon":193},[197],{"name":198,"role":47,"phone":199,"phoneExt":31,"email":200},"Begoña Taboada, PhD","+34 981 95 00 00","btabval@gmail.com",{"facility":202,"status":88,"city":203,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Genesis Care","Seville",{"type":62,"coordinates":205},[206,207],-5.97317,37.38283,{"lat":207,"lon":206},[210],{"name":211,"role":47,"phone":212,"phoneExt":31,"email":213},"Jose Antonio González, PhD","+34 954 46 70 53","sevilla@genesiscare.es",{"facility":215,"status":56,"city":203,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":216,"geoPoint":218,"contacts":219},"Hospital Universitario Virgen del Rocio",{"type":62,"coordinates":217},[206,207],{"lat":207,"lon":206},[220],{"name":221,"role":47,"phone":222,"phoneExt":31,"email":223},"Jose Luis Lopez Guerra, PhD","+34 955 01 20 00","chanodetriana@yahoo.es",{"facility":225,"status":88,"city":226,"state":31,"zip":31,"country":59,"countryCode":60,"cosmosGeoPoint":227,"geoPoint":231,"contacts":232},"Hospital La Fe","Valencia",{"type":62,"coordinates":228},[229,230],-0.37966,39.47391,{"lat":230,"lon":229},[233],{"name":234,"role":47,"phone":235,"phoneExt":31,"email":236},"Rodolfo Chicas, PhD","+34 961 24 40 00","rchicas@ufm.edu",{"type":238,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[240],{"name":241,"class":6},"Spanish Lung Cancer Group","100594165","phase-3-dose-escalation-radiotherapy-in-limited-stage-small-cell-lung-cancer-a-phase-iii-randomized-trial-100594165",false,"NCT07015892","Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial","Phase III Randomized Clinical Trial to Evaluate the Efficacy and Safety of Twice-Daily Hyperfractionated Dose-Escalated Thoracic Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer (ESCALADOR Study)","ESCALADOR","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of small cell lung cancer (SCLC)\n* Limited-stage disease (Stage I-III; any T, any N, M0), eligible for definitive radiotherapy\n* Measurable disease according to RECIST 1.1\n* Age ≥18 years\n* ECOG performance status 0-2\n* No prior thoracic radiotherapy\n* Signed informed consent\n* Adequate hematologic function: WBC ≥3.0×10⁹\u002FL, neutrophils ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL, hemoglobin ≥90 g\u002FL\n* Adequate liver and renal function: total bilirubin ≤1.5×ULN, AST\u002FALT ≤1.5×ULN, creatinine normal or CrCl ≥60 mL\u002Fmin\n* Pulmonary function: FEV1 \\>1 L or \\>30% predicted; DLCO \\>30% predicted\n\nExclusion Criteria:\n\n* Prior surgery or radiotherapy for any lung cancer (SCLC or NSCLC)\n* Presence of malignant cells in pleural or pericardial effusion\n* Serious uncontrolled systemic disorders (e.g., active infection, unstable cardiovascular disease)\n* Medical, psychological, or social conditions that could interfere with compliance\n* Active malignancy other than SCLC (except localized prostate\u002Fbreast cancer or basal cell carcinoma)\n* Refusal or inability to sign informed consent","ALL","18 Years",{"count":253,"type":254},300,"ESTIMATED","INTERVENTIONAL",[257],"PHASE3","This is a phase III clinical trial that aims to evaluate whether increasing the dose of radiotherapy given twice a day can improve treatment outcomes in patients with localized small cell lung cancer (SCLC). All patients will receive standard chemotherapy with cisplatin and etoposide and will be randomly assigned to one of three radiotherapy regimens.\n\nThe main objective is to determine whether this intensified radiotherapy improves progression-free survival and overall survival. The study will also compare two different dose escalation strategies and assess treatment side effects and patients' quality of life.\n\nThis research may help identify a more effective treatment approach for patients with limited-stage SCLC and could contribute to improving long-term survival in this aggressive type of cancer",[260],"Small Cell Lung Carcinoma",[262,263,264,265],"Radiotherapy","Chemoradiotherapy","Dose-Response Relationship","Radiation","2026-03-25",{"date":268,"type":269},"2026-03-31","ACTUAL",{"date":271,"type":269},"2026-03-01",{"date":273,"type":254},"2028-12-31",{"name":5,"class":6},13]